<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1174</ReferenceId>
        <DateLastUpdated>2016-11-03-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15866072</PubmedId>
            <Abstract>We produced nine monoclonal antibodies (MAbs) directed against the West Nile virus E glycoprotein using three different immunization strategies: inactivated virus, naked DNA, and recombinant protein. Most of the MAbs bound to conformation dependent epitopes in domain III of the E protein. Four of the MAbs neutralized WNV infection and bound to the same region of domain III with high affinity. The neutralizing MAbs were obtained from mice immunized with inactivated virus alone or in combination with a DNA plasmid. In contrast, MAbs obtained by immunization with a soluble version of the E glycoprotein did not exhibit neutralizing activity. These non-neutralizing antibodies were cross-reactive with several other flaviviruses, including Saint Louis encephalitis, Japanese encephalitis, Yellow Fever and Powassan viruses. Interestingly, some non-neutralizing MAbs bound with high affinity to domains I or III, indicating that both affinity and the precise epitope recognized by an antibody are important determinants of WNV neutralization.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>70-82</ArticlePages>
            <ArticleTitle>Characterization of neutralizing antibodies to West Nile virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>SÃ¡nchez</LastName>
                    <ForeName>Melissa D</ForeName>
                </Author>
                <Author>
                    <LastName>Pierson</LastName>
                    <ForeName>Theodore C</ForeName>
                </Author>
                <Author>
                    <LastName>McAllister</LastName>
                    <ForeName>Douglas</ForeName>
                </Author>
                <Author>
                    <LastName>Hanna</LastName>
                    <ForeName>Sheri L</ForeName>
                </Author>
                <Author>
                    <LastName>Puffer</LastName>
                    <ForeName>Bridget A</ForeName>
                </Author>
                <Author>
                    <LastName>Valentine</LastName>
                    <ForeName>Laura E</ForeName>
                </Author>
                <Author>
                    <LastName>Murtadha</LastName>
                    <ForeName>Mariam M</ForeName>
                </Author>
                <Author>
                    <LastName>Hoxie</LastName>
                    <ForeName>James A</ForeName>
                </Author>
                <Author>
                    <LastName>Doms</LastName>
                    <ForeName>Robert W</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antibodies, Viral;Antigens, Viral;Epitopes;Glycoproteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Monoclonal(immunology); Antibodies, Viral(immunology); Antigens, Viral(immunology); Cross Reactions; Encephalitis Virus, Japanese(immunology); Encephalitis Virus, St. Louis(immunology); Encephalitis Viruses, Tick-Borne(immunology); Enzyme-Linked Immunosorbent Assay; Epitope Mapping; Epitopes(immunology); Glycoproteins(immunology); Mice; Neutralization Tests; Protein Structure, Tertiary; West Nile virus(immunology); Yellow fever virus(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>336</Volume>
                <Issue>1</Issue>
                <Title>Virology</Title>
                <Issn>1096-0341</Issn>
                <MedlineTa>Virology</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>T330, T332, S306, K307</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>YP_001527880.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11082</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 3</LocationOfData>
                <EpitopeId>110489</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>These residues are located on Domain III (aa296-415) of source antigen ectodomain, forming a continuous patch on the solvent-exposed surface.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <BCellId>16657</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11082</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>4 doses intramuscularly 3 wk apart, followed by 2 doses I.P. and a last boost I.V. 4 days prior to spleen removal for hybridoma production.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunogen was a formalin-inactivated virus vaccine, licensed for use in horses (West Nile innovator). One of the mAbs (11C2) was obtained from a mouse primed with plasmid DNA encoding prM and E protiens from WNV before formalin-inactivated virus immunizations. The dose schedule and route in that case was: 3 doses I.M. of DNA, 3 doses of virus I.M., 1 dose of virus  I.P. and a final boost with virus I.V, all 3 wk apart.  Immune splenocytes were used for hybridoma production by fusion with SP2 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Wild type E protein expressed in the context of subviral particles (SVP) are recognized by 4 mAbs showing neutralizing activity, while mutant E protein harboring mutations at epitopic residues are not recognized. Mutations at residues K307 and T330 abolish recognition by all the 4 mAbs, while mutation at S306 and T332 abolishes recognition of 3 of the mAbs. All the 4 mAbs are of IgG1 isotype. These mAbs inhibit the binding of each other to SVPs, confirming that they recognize a similar or adjacent epitope. The reactivity against the source protein by western blot was maintained in partial denaturing conditions but lost in denaturing conditions. They also recognize the source protein by immunofluorescence with infected cells and WNV SVPs expressing lineage II E protein, but not other closely related flaviviruses. On the other hand, other antibodies directed against domain III, but without neutralizing activity, are reactive with Saint Louis and Japanese encephalitis viruses, as well as Yellow Fever and Powasan viruses, but not other virus tested (Dengue 2, equine encephalitis, etc).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>8B10, 17C8, 10C5, 11C2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Major envelope protein E</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>YP_001527880.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11082</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>16656</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11082</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>4 doses intramuscularly 3 wk apart, followed by 2 doses I.P. and a last boost I.V. 4 days prior to spleen removal for hybridoma production.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunogen was a formalin-inactivated virus vaccine, licensed for use in horses (West Nile innovator). One of the mAbs (11C2) was obtained from a mouse primed with plasmid DNA encoding prM and E protiens from WNV before formalin-inactivated virus immunizations. The dose schedule and route in that case was: 3 doses I.M. of DNA, 3 doses of virus I.M., 1 dose of virus  I.P. and a final boost with virus I.V, all 3 wk apart.  Immune splenocytes were used for hybridoma production by fusion with SP2 myeloma cells.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>E.coli expressing  E protein fragments were lysed and blotted under partially denaturing conditions. Domain III fragment is recognized by 6 out of 9 mAbs, 4 of which show neutralizing activity.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>8B10, 17C8, 10C5, 11C2 and others</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Major envelope protein E</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>YP_001527880.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11082</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

